Keh-Sung Tsai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Keh-Sung Tsai has a total of 660 co-authors. Here are the top co-authors by number of shared publications:
- Rong-Sen Yang
Department of Orthopaedics, College of Medicine, National Taiwan University, Taipei, Taiwan
47 shared publications - Shing-Hwa Liu
Institute of Toxicology, College of Medicine, National Taiwan University, Taipei, Taiwan; Department of Medical Research, China Medical University Hospital, China Medical University, Taichung, Taiwan; Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan
23 shared publications - Ding-Cheng Chan
Department of Geriatrics and Gerontology, National Taiwan University Hospital, Taipei, Taiwan
11 shared publications Jung-Fu Chen
9 shared publications- Jau-Tsuen Kao
Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan
8 shared publications Jawl-Shan Hwang
8 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1930247
High genetic predisposition and vertebral fracture burden in pregnancy and lactation-associated osteoporosis: clinical insights from a Taiwanese cohort
Background: Pregnancy and lactation-associated osteoporosis (PLO) is a rare disorder causing rapid bone loss and severe fragility fractures. While familial clusterings suggest genetic susceptibility, the specific clinical features, genetic landscape, and skeletal recovery trajectory of PLO remain poorly characterized in non-Caucasian populations. This study aimed to evaluate a Taiwanese PLO cohort to optimize diagnostic awareness. Methods: Eleven postpartum women with PLO were evaluated using bone densitometry and spinal imaging. Whole-exome sequencing was performed utilizing a targeted 398-gene skeletal disease virtual panel. Patients were followed longitudinally for a median of 25 months during lactation cessation and/or targeted bone therapy. Results: Seven women developed symptoms after their first pregnancy and four after their second. Vertebral fractures occurred in 91% (10/11) of patients, 80% (8/10) of whom had multi-level involvement predominantly localized to the thoracolumbar spine (T3-L5, peaking at T11-L2). Baseline lumbar bone mineral density (BMD) was significantly lower than hip sites ( P = 0.018). Genetic variants were identified in 10 of 11 patients (91%), with six individuals harboring pathogenic variants in WNT1 , LRP5 , COL10A1 , LTBP3 , and CALCR . Patients with pathogenic variants exhibited significantly lower lumbar spine BMD than those without (Z-scores: -3.7 vs. -3.0; P = 0.043). Post-treatment, the cohort’s median Z-score improved from -3.5 to -2.3 ( P = 0.005), though none achieved a score above -1.0. Conclusions: Our findings suggest a significant genetic burden associated with PLO, potentially revealed by pregnancy and lactation stressors. The predominance of vertebral bone loss highlights acute postpartum back pain as a notable clinical sign warranting further investigation. Optimizing long-term maternal outcomes may require rapid diagnostic evaluation, prompt lactation cessation, and the future integration of genotype-informed management strategies.
- 6 October 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1930247
Open AccessHigh genetic predisposition and vertebral fracture burden in pregnancy and lactation-associated osteoporosis: clinical insights from a Taiwanese cohort
Background: Pregnancy and lactation-associated osteoporosis (PLO) is a rare disorder causing rapid bone loss and severe fragility fractures. While familial clusterings suggest genetic susceptibility, the specific clinical features, genetic landscape, and skeletal recovery trajectory of PLO remain poorly characterized in non-Caucasian populations. This study aimed to evaluate a Taiwanese PLO cohort to optimize diagnostic awareness. Methods: Eleven postpartum women with PLO were evaluated using bone densitometry and spinal imaging. Whole-exome sequencing was performed utilizing a targeted 398-gene skeletal disease virtual panel. Patients were followed longitudinally for a median of 25 months during lactation cessation and/or targeted bone therapy. Results: Seven women developed symptoms after their first pregnancy and four after their second. Vertebral fractures occurred in 91% (10/11) of patients, 80% (8/10) of whom had multi-level involvement predominantly localized to the thoracolumbar spine (T3-L5, peaking at T11-L2). Baseline lumbar bone mineral density (BMD) was significantly lower than hip sites ( P = 0.018). Genetic variants were identified in 10 of 11 patients (91%), with six individuals harboring pathogenic variants in WNT1 , LRP5 , COL10A1 , LTBP3 , and CALCR . Patients with pathogenic variants exhibited significantly lower lumbar spine BMD than those without (Z-scores: -3.7 vs. -3.0; P = 0.043). Post-treatment, the cohort’s median Z-score improved from -3.5 to -2.3 ( P = 0.005), though none achieved a score above -1.0. Conclusions: Our findings suggest a significant genetic burden associated with PLO, potentially revealed by pregnancy and lactation stressors. The predominance of vertebral bone loss highlights acute postpartum back pain as a notable clinical sign warranting further investigation. Optimizing long-term maternal outcomes may require rapid diagnostic evaluation, prompt lactation cessation, and the future integration of genotype-informed management strategies.
- Open Access
- 16 March 2024
- Published by Elsevier in Osteoporosis and Sarcopenia
- Vol. 10 (1) , 3-10
Asia-Pacific consensus on long-term and sequential therapy for osteoporosis
- 16 March 2024
- Published by Elsevier in Osteoporosis and Sarcopenia
- Vol. 10 (1) , 3-10
Open AccessAsia-Pacific consensus on long-term and sequential therapy for osteoporosis
- 29 January 2021
- Published by World Scientific Pub Co Pte Ltd
- p. 3-10
Epidemiology of Osteoporosis in Taiwan
- 29 January 2021
- Published by World Scientific Pub Co Pte Ltd
- p. 3-10
Epidemiology of Osteoporosis in Taiwan
- Open Access
- 1 January 2021
- Published by Elsevier in Journal of Clinical Densitometry
- Vol. 24 (1) , 3-13
Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region
- 1 January 2021
- Published by Elsevier in Journal of Clinical Densitometry
- Vol. 24 (1) , 3-13
Open AccessConsensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region
- 23 October 2019
- Published by Springer Nature in Osteoporosis International
- Vol. 31 (1) , 193-201
Racial difference in bioavailability of oral ibandronate between Caucasian and Taiwanese postmenopausal women
Following 150 mg of oral ibandronate, Taiwanese females have greater serum and urine levels of this drug and bone resorption marker suppression than Caucasian women. These inter-ethnic differences seems to be partly explained by a 2.48-fold higher bioavailability of ibandronate in Taiwanese postmenopausal women.
- 23 October 2019
- Published by Springer Nature in Osteoporosis International
- Vol. 31 (1) , 193-201
Racial difference in bioavailability of oral ibandronate between Caucasian and Taiwanese postmenopausal women
Following 150 mg of oral ibandronate, Taiwanese females have greater serum and urine levels of this drug and bone resorption marker suppression than Caucasian women. These inter-ethnic differences seems to be partly explained by a 2.48-fold higher bioavailability of ibandronate in Taiwanese postmenopausal women.
- 1 September 2019
- Published by Elsevier in Journal of the American Medical Directors Association
- Vol. 20 (9) , 1129-1136.e1
Risk Factors for Poor Functional Recovery, Mortality, Recurrent Fractures, and Falls Among Patients Participating in a Fracture Liaison Service Program
- 1 September 2019
- Published by Elsevier in Journal of the American Medical Directors Association
- Vol. 20 (9) , 1129-1136.e1
Risk Factors for Poor Functional Recovery, Mortality, Recurrent Fractures, and Falls Among Patients Participating in a Fracture Liaison Service Program
- 5 August 2019
- Published by Springer Nature in Osteoporosis International
- Vol. 30 (11) , 2289-2297
Serum fibroblast growth factor 23 and mineral metabolism in patients with euthyroid Graves’ diseases: a case-control study
Summary This study investigated the alterations of mineral metabolism in patients with Graves’ disease (GD) who achieved euthyroidism. They had higher fibroblast growth factor 23 (FGF23) and phosphorus as compared with healthy subjects. Serum FGF23 was negatively correlated with serum phosphorus. These indicated abnormal mineral metabolism even after 1.6 years of euthyroid status. Introduction FGF23 is involved in the mineral homeostasis, especially the regulation of serum phosphorus. Graves’ disease (GD) is associated with accelerated bone turnover, hyperphosphatemia, and elevated serum FGF23. Evidence suggested that serum FGF23 decreased after a 3-month treatment of GD. However, it remains unclear whether serum FGF23, serum phosphorus, and other markers of mineral metabolism will be normalized after euthyroid status achieved. Methods A total of 62 patients with euthyroid GD and 62 healthy control subjects were enrolled, and the median duration of euthyroid status was 1.6 years. Endocrine profiles including thyroid function test, autoantibodies, serum FGF23, and bone turnover markers were obtained and compared between the two groups. Results Euthyroid GD patients had significantly higher serum FGF23 and phosphorus, and lower 25-hydroxyvitamin D (25(OH)D) and intact parathyroid hormone (iPTH) levels as compared with the control group. Serum FGF23 was significantly and negatively correlated with phosphorus level after adjusted for age, gender, calcium, iPTH, and 25(OH)D in the euthyroid GD group. Conclusion Serum phosphorus and FGF23 levels remain higher in GD patients even after euthyroid status has been achieved for a median of 1.6 years. Serum FGF23 was negatively correlated with serum phosphorus in euthyroid GD patients. Underlying mechanisms warrant further investigations. Trial registration Registration number: NCT01660308 and NCT02620085
- 5 August 2019
- Published by Springer Nature in Osteoporosis International
- Vol. 30 (11) , 2289-2297
Serum fibroblast growth factor 23 and mineral metabolism in patients with euthyroid Graves’ diseases: a case-control study
Summary This study investigated the alterations of mineral metabolism in patients with Graves’ disease (GD) who achieved euthyroidism. They had higher fibroblast growth factor 23 (FGF23) and phosphorus as compared with healthy subjects. Serum FGF23 was negatively correlated with serum phosphorus. These indicated abnormal mineral metabolism even after 1.6 years of euthyroid status. Introduction FGF23 is involved in the mineral homeostasis, especially the regulation of serum phosphorus. Graves’ disease (GD) is associated with accelerated bone turnover, hyperphosphatemia, and elevated serum FGF23. Evidence suggested that serum FGF23 decreased after a 3-month treatment of GD. However, it remains unclear whether serum FGF23, serum phosphorus, and other markers of mineral metabolism will be normalized after euthyroid status achieved. Methods A total of 62 patients with euthyroid GD and 62 healthy control subjects were enrolled, and the median duration of euthyroid status was 1.6 years. Endocrine profiles including thyroid function test, autoantibodies, serum FGF23, and bone turnover markers were obtained and compared between the two groups. Results Euthyroid GD patients had significantly higher serum FGF23 and phosphorus, and lower 25-hydroxyvitamin D (25(OH)D) and intact parathyroid hormone (iPTH) levels as compared with the control group. Serum FGF23 was significantly and negatively correlated with phosphorus level after adjusted for age, gender, calcium, iPTH, and 25(OH)D in the euthyroid GD group. Conclusion Serum phosphorus and FGF23 levels remain higher in GD patients even after euthyroid status has been achieved for a median of 1.6 years. Serum FGF23 was negatively correlated with serum phosphorus in euthyroid GD patients. Underlying mechanisms warrant further investigations. Trial registration Registration number: NCT01660308 and NCT02620085
- Open Access
- 12 July 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-10
Fracture types affect clinical outcomes of patients managed within the fracture liaison and osteoporosis medication management services
Osteoporosis medication in fragility fracture patients is associated with better outcomes. However, limited studies have investigated whether fracture types affect outcomes among patients undergoing treatment. We performed a secondary data analysis on participants from a fracture liaison service and an osteoporosis medication management service. Participants (n = 974) were regrouped into hip fracture (HF), vertebral fracture (VF), HF + VF, and NO HF/VF groups at baseline. Bivariate and multivariate logistic regressions were performed to identify baseline correlates on one-year mortality, incident refractures, and falls. Baseline characteristics were different among fracture groups. The HF group was oldest, with the lowest body mass index (BMI), lowest FRAX® T-score and had the highest 10-year fracture risk. After intervention, the HF group still had the highest mortality, but the HF + VF group had the highest refracture and incident fall rates. In the multivariate regression analysis, prevalent HF and VF, lower BMI and albumin level, and having chronic kidney disease or cancer were associated with higher mortality rates. HF + VF patients had the highest refracture risk. Prevalent HF and VF, older age and higher BMI, and having cancer or osteoarthritis were associated with a greater fall risk. HF and VF are associated with adverse outcomes, even under an optimal fracture care.
- 12 July 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-10
Open AccessFracture types affect clinical outcomes of patients managed within the fracture liaison and osteoporosis medication management services
Osteoporosis medication in fragility fracture patients is associated with better outcomes. However, limited studies have investigated whether fracture types affect outcomes among patients undergoing treatment. We performed a secondary data analysis on participants from a fracture liaison service and an osteoporosis medication management service. Participants (n = 974) were regrouped into hip fracture (HF), vertebral fracture (VF), HF + VF, and NO HF/VF groups at baseline. Bivariate and multivariate logistic regressions were performed to identify baseline correlates on one-year mortality, incident refractures, and falls. Baseline characteristics were different among fracture groups. The HF group was oldest, with the lowest body mass index (BMI), lowest FRAX® T-score and had the highest 10-year fracture risk. After intervention, the HF group still had the highest mortality, but the HF + VF group had the highest refracture and incident fall rates. In the multivariate regression analysis, prevalent HF and VF, lower BMI and albumin level, and having chronic kidney disease or cancer were associated with higher mortality rates. HF + VF patients had the highest refracture risk. Prevalent HF and VF, older age and higher BMI, and having cancer or osteoarthritis were associated with a greater fall risk. HF and VF are associated with adverse outcomes, even under an optimal fracture care.
- 16 November 2018
- Published by Springer Nature in Archives of Osteoporosis
- Vol. 13 (1) , 126
Chronic kidney disease predicts a lower probability of improvement in patient-reported experience measures among patients with fractures: a prospective multicenter cohort study
Patient-reported experience measures (PREMs) are integral component of care for fracture patients. Using a multicenter cohort, we showed that the presence of chronic kidney disease (CKD) attenuated the probability of PREM improvement in fracture patients.
- 16 November 2018
- Published by Springer Nature in Archives of Osteoporosis
- Vol. 13 (1) , 126
Chronic kidney disease predicts a lower probability of improvement in patient-reported experience measures among patients with fractures: a prospective multicenter cohort study
Patient-reported experience measures (PREMs) are integral component of care for fracture patients. Using a multicenter cohort, we showed that the presence of chronic kidney disease (CKD) attenuated the probability of PREM improvement in fracture patients.
- Open Access
- 3 July 2018
- Published by Springer Nature in Archives of Osteoporosis
- Vol. 13 (1) , 73
Correction to: Consensus on best practice standards for Fracture Liaison Service in the Asia-Pacific region
In this article the name of the sixth author, E. Michael Lewiecki was rendered incorrectly. The publisher regrets this error and apologizes for the inconvenience caused.
- 3 July 2018
- Published by Springer Nature in Archives of Osteoporosis
- Vol. 13 (1) , 73
Open AccessCorrection to: Consensus on best practice standards for Fracture Liaison Service in the Asia-Pacific region
In this article the name of the sixth author, E. Michael Lewiecki was rendered incorrectly. The publisher regrets this error and apologizes for the inconvenience caused.